7-year data show sustained RFS, DMFS, and OS benefits across subgroups.
ONCOLOGY
Fully funded by 
Content independently selected
-
Long-term data support adjuvant ipilimumab for stage III melanoma -
Melanoma: dual BRAF/MEK inhibition tied to greater cardiovascular risk Meta-analysis shows higher risk vs BRAF inhibitors alone.
-
Melanoma: dual BRAF/MEK inhibition extends survival in meta-analysis A summary of the most recent randomized controlled trials.
-
T2 melanoma: young age, LVI among predictors of SLN metastasis Factors can help weigh need for biopsy among elders with low-risk disease.
-
NICE approves cemiplimab for cutaneous squamous cell carcinoma While more mature data is awaited, the treatment will be available within the Cancer Drugs Fund
-
Advanced melanoma: real-world data confirm pembrolizumab benefit Insights into positive prognostic factors.
-
Melanoma: 18F-FDG PET/CT predictive of response to immunotherapy in a French study A useful tool for optimizing patient management.
-
Advanced melanoma: pembrolizumab superior to ipilimumab in 5-year follow-up Further support for the use of pembrolizumab.
-
Screening for malignant melanoma is currently practised in many countries despite lack of evidence on benefits and risks.
-
Advanced melanoma: immunotherapies preferred in real-world study US Oncology Network data from 2014 through 2016.
-
Meta-analysis: surgery, Mohs most effective for basal cell carcinoma Review offers a comparison of multiple treatment strategies.
-
European organizations issue guidelines for basal cell carcinoma Recent advances spur consensus-based interdisciplinary guidelines.
-
Thick melanoma: 2- and 4-cm margins yield similar long-term outcomes Data at a median of 19.6 years confirm earlier findings.
-
Melanoma: cutaneous events predict better response to immunotherapy Data show better PFS with pembrolizumab or nivolumab.